APO Research
Talk to an analyst

APO RESEARCH · REPORT

Favipiravir

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Favipiravir Market Outlook and Growth Opportunities 2026

29 December 2025190 pages

Choose your research edition.

Industry ResearchFavipiravir Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Favipiravir Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Favipiravir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Favipiravir Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Favipiravir Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Favipiravir market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Favipiravir market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Favipiravir market include ChemRar Group, Cipla, Dr. Reddy, Fujifilm, Glenmark, Lupin, R-Pharma, Sun Pharma and Hisun Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Favipiravir market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Favipiravir and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Favipiravir sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Favipiravir market size, projected growth trends, production technologies, key applications, and end-use industries.

Favipiravir Segment by Company

ChemRar Group

Cipla

Dr. Reddy

Fujifilm

Glenmark

Lupin

R-Pharma

Sun Pharma

Hisun Pharm

Favipiravir Segment by Type

Brand Drug

Generic Drug

Favipiravir Segment by Application

Influenza Viruses

COVID-19

Others

Favipiravir Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Favipiravir status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Favipiravir market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Favipiravir significant trends, drivers, influence factors in global and regions.

6. To analyze Favipiravir competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Favipiravir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Favipiravir and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Favipiravir.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Favipiravir market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Favipiravir industry.

Chapter 3: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Favipiravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Favipiravir in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Favipiravir Industry Trends Table 2. Favipiravir Industry Drivers Table 3. Favipiravir Industry Opportunities and Challenges Table 4. Favipiravir Industry Restraints Table 5. Global Favipiravir Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Favipiravir Revenue Share by Company (2021-2026) Table 7. Global Favipiravir Sales Volume by Company (K Pcs) & (2021-2026) Table 8. Global Favipiravir Sales Volume Share by Company (2021-2026) Table 9. Global Favipiravir Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Favipiravir Company Ranking, (2024-2026) & (USD Million) Table 11. Global Favipiravir Key Company Manufacturing Base & Headquarters Table 12. Global Favipiravir Company, Product Type & Application Table 13. Global Favipiravir Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Favipiravir by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Brand Drug Table 18. Significant Companies of Generic Drug Table 19. Global Favipiravir Sales Volume by Type 2021 VS 2025 VS 2032 (K Pcs) Table 20. Global Favipiravir Sales Volume by Type (2021-2026) & (K Pcs) Table 21. Global Favipiravir Sales Volume by Type (2027-2032) & (K Pcs) Table 22. Global Favipiravir Sales Volume Share by Type (2021-2026) Table 23. Global Favipiravir Sales Volume Share by Type (2027-2032) Table 24. Global Favipiravir Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Favipiravir Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Favipiravir Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Favipiravir Sales Value Share by Type (2021-2026) Table 28. Global Favipiravir Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Influenza Viruses Table 30. Significant Companies of COVID-19 Table 31. Significant Companies of Others Table 32. Global Favipiravir Sales Volume by Application 2021 VS 2025 VS 2032 (K Pcs) Table 33. Global Favipiravir Sales Volume by Application (2021-2026) & (K Pcs) Table 34. Global Favipiravir Sales Volume by Application (2027-2032) & (K Pcs) Table 35. Global Favipiravir Sales Volume Share by Application (2021-2026) Table 36. Global Favipiravir Sales Volume Share by Application (2027-2032) Table 37. Global Favipiravir Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Favipiravir Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Favipiravir Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Favipiravir Sales Value Share by Application (2021-2026) Table 41. Global Favipiravir Sales Value Share by Application (2027-2032) Table 42. Global Favipiravir Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 43. Global Favipiravir Sales by Region (2021-2026) & (K Pcs) Table 44. Global Favipiravir Sales Market Share by Region (2021-2026) Table 45. Global Favipiravir Sales by Region (2027-2032) & (K Pcs) Table 46. Global Favipiravir Sales Market Share by Region (2027-2032) Table 47. Global Favipiravir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Favipiravir Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Favipiravir Sales Value Share by Region (2021-2026) Table 50. Global Favipiravir Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Favipiravir Sales Value Share by Region (2027-2032) Table 52. Global Favipiravir Market Average Price (US$/Pcs) by Region (2021-2026) Table 53. Global Favipiravir Market Average Price (US$/Pcs) by Region (2027-2032) Table 54. Global Favipiravir Sales by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 55. Global Favipiravir Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Favipiravir Sales by Country (2021-2026) & (K Pcs) Table 57. Global Favipiravir Sales Market Share by Country (2021-2026) Table 58. Global Favipiravir Sales by Country (2027-2032) & (K Pcs) Table 59. Global Favipiravir Sales Market Share by Country (2027-2032) Table 60. Global Favipiravir Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Favipiravir Sales Value Market Share by Country (2021-2026) Table 62. Global Favipiravir Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Favipiravir Sales Value Market Share by Country (2027-2032) Table 64. ChemRar Group Company Information Table 65. ChemRar Group Business Overview Table 66. ChemRar Group Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 67. ChemRar Group Favipiravir Product Portfolio Table 68. ChemRar Group Recent Development Table 69. Cipla Company Information Table 70. Cipla Business Overview Table 71. Cipla Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 72. Cipla Favipiravir Product Portfolio Table 73. Cipla Recent Development Table 74. Dr. Reddy Company Information Table 75. Dr. Reddy Business Overview Table 76. Dr. Reddy Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 77. Dr. Reddy Favipiravir Product Portfolio Table 78. Dr. Reddy Recent Development Table 79. Fujifilm Company Information Table 80. Fujifilm Business Overview Table 81. Fujifilm Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 82. Fujifilm Favipiravir Product Portfolio Table 83. Fujifilm Recent Development Table 84. Glenmark Company Information Table 85. Glenmark Business Overview Table 86. Glenmark Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 87. Glenmark Favipiravir Product Portfolio Table 88. Glenmark Recent Development Table 89. Lupin Company Information Table 90. Lupin Business Overview Table 91. Lupin Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 92. Lupin Favipiravir Product Portfolio Table 93. Lupin Recent Development Table 94. R-Pharma Company Information Table 95. R-Pharma Business Overview Table 96. R-Pharma Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 97. R-Pharma Favipiravir Product Portfolio Table 98. R-Pharma Recent Development Table 99. Sun Pharma Company Information Table 100. Sun Pharma Business Overview Table 101. Sun Pharma Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 102. Sun Pharma Favipiravir Product Portfolio Table 103. Sun Pharma Recent Development Table 104. Hisun Pharm Company Information Table 105. Hisun Pharm Business Overview Table 106. Hisun Pharm Favipiravir Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 107. Hisun Pharm Favipiravir Product Portfolio Table 108. Hisun Pharm Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Favipiravir Distributors List Table 112. Favipiravir Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Favipiravir Product Image Figure 2. Global Favipiravir Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 4. Global Favipiravir Sales (2021-2032) & (K Pcs) Figure 5. Global Favipiravir Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Favipiravir Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Brand Drug Image Figure 10. Generic Drug Image Figure 11. Global Favipiravir Sales Volume by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 12. Global Favipiravir Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Favipiravir Sales Volume Share by Type (2021-2032) Figure 14. Global Favipiravir Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Favipiravir Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Favipiravir Sales Value Share by Type (2021-2032) Figure 17. Influenza Viruses Image Figure 18. COVID-19 Image Figure 19. Others Image Figure 20. Global Favipiravir Sales Volume by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 21. Global Favipiravir Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Favipiravir Sales Volume Share by Application (2021-2032) Figure 23. Global Favipiravir Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Favipiravir Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Favipiravir Sales Value Share by Application (2021-2032) Figure 26. Global Favipiravir Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Figure 27. Global Favipiravir Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Favipiravir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Favipiravir Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 31. North America Favipiravir Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Favipiravir Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Favipiravir Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 37. South America Favipiravir Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Favipiravir Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Favipiravir Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Favipiravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Favipiravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Favipiravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Favipiravir Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Favipiravir Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Brand Drug
  • Generic Drug
Applications
  • Influenza Viruses
  • COVID-19
  • Others
Companies covered
  • ChemRar Group
  • Cipla
  • Dr. Reddy
  • Fujifilm
  • Glenmark
  • Lupin
  • R-Pharma
  • Sun Pharma
  • Hisun Pharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Favipiravir Sales Value (2021-2032)
  4. 1.2.2 Global Favipiravir Sales Volume (2021-2032)
  5. 1.2.3 Global Favipiravir Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Favipiravir Market Dynamics
  1. 2.1 Favipiravir Industry Trends
  2. 2.2 Favipiravir Industry Drivers
  3. 2.3 Favipiravir Industry Opportunities and Challenges
  4. 2.4 Favipiravir Industry Restraints
3 Favipiravir Market by Company
  1. 3.1 Global Favipiravir Company Revenue Ranking in 2025
  2. 3.2 Global Favipiravir Revenue by Company (2021-2026)
  3. 3.3 Global Favipiravir Sales Volume by Company (2021-2026)
  4. 3.4 Global Favipiravir Average Price by Company (2021-2026)
  5. 3.5 Global Favipiravir Company Ranking (2024-2026)
  6. 3.6 Global Favipiravir Company Manufacturing Base and Headquarters
  7. 3.7 Global Favipiravir Company Product Type and Application
  8. 3.8 Global Favipiravir Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Favipiravir Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Favipiravir Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Favipiravir Market by Type
  1. 4.1 Favipiravir Type Introduction
  2. 4.1.1 Brand Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Favipiravir Sales Volume by Type
  5. 4.2.1 Global Favipiravir Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Favipiravir Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Favipiravir Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Favipiravir Sales Value by Type
  9. 4.3.1 Global Favipiravir Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Favipiravir Sales Value by Type (2021-2032)
  11. 4.3.3 Global Favipiravir Sales Value Share by Type (2021-2032)
5 Favipiravir Market by Application
  1. 5.1 Favipiravir Application Introduction
  2. 5.1.1 Influenza Viruses
  3. 5.1.2 COVID-19
  4. 5.1.3 Others
  5. 5.2 Global Favipiravir Sales Volume by Application
  6. 5.2.1 Global Favipiravir Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Favipiravir Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Favipiravir Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Favipiravir Sales Value by Application
  10. 5.3.1 Global Favipiravir Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Favipiravir Sales Value by Application (2021-2032)
  12. 5.3.3 Global Favipiravir Sales Value Share by Application (2021-2032)
6 Favipiravir Regional Sales and Value Analysis
  1. 6.1 Global Favipiravir Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Favipiravir Sales by Region (2021-2032)
  3. 6.2.1 Global Favipiravir Sales by Region: 2021-2026
  4. 6.2.2 Global Favipiravir Sales by Region (2027-2032)
  5. 6.3 Global Favipiravir Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Favipiravir Sales Value by Region (2021-2032)
  7. 6.4.1 Global Favipiravir Sales Value by Region: 2021-2026
  8. 6.4.2 Global Favipiravir Sales Value by Region (2027-2032)
  9. 6.5 Global Favipiravir Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Favipiravir Sales Value (2021-2032)
  12. 6.6.2 North America Favipiravir Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Favipiravir Sales Value (2021-2032)
  15. 6.7.2 Europe Favipiravir Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Favipiravir Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Favipiravir Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Favipiravir Sales Value (2021-2032)
  21. 6.9.2 South America Favipiravir Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Favipiravir Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Favipiravir Sales Value Share by Country, 2025 VS 2032
7 Favipiravir Country-level Sales and Value Analysis
  1. 7.1 Global Favipiravir Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Favipiravir Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Favipiravir Sales by Country (2021-2032)
  4. 7.3.1 Global Favipiravir Sales by Country (2021-2026)
  5. 7.3.2 Global Favipiravir Sales by Country (2027-2032)
  6. 7.4 Global Favipiravir Sales Value by Country (2021-2032)
  7. 7.4.1 Global Favipiravir Sales Value by Country (2021-2026)
  8. 7.4.2 Global Favipiravir Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Favipiravir Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Favipiravir Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Favipiravir Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Favipiravir Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Favipiravir Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Favipiravir Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Favipiravir Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Favipiravir Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Favipiravir Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Favipiravir Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Favipiravir Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Favipiravir Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Favipiravir Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Favipiravir Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Favipiravir Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Favipiravir Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Favipiravir Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Favipiravir Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Favipiravir Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Favipiravir Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Favipiravir Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Favipiravir Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Favipiravir Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Favipiravir Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Favipiravir Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Favipiravir Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Favipiravir Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Favipiravir Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Favipiravir Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Favipiravir Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Favipiravir Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Favipiravir Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Favipiravir Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Favipiravir Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Favipiravir Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Favipiravir Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Favipiravir Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Favipiravir Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Favipiravir Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Favipiravir Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Favipiravir Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Favipiravir Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Favipiravir Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Favipiravir Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Favipiravir Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Favipiravir Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Favipiravir Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Favipiravir Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Favipiravir Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Favipiravir Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Favipiravir Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Favipiravir Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Favipiravir Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Favipiravir Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Favipiravir Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Favipiravir Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Favipiravir Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Favipiravir Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Favipiravir Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Favipiravir Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Favipiravir Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Favipiravir Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Favipiravir Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Favipiravir Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Favipiravir Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Favipiravir Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Favipiravir Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Favipiravir Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Favipiravir Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Favipiravir Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Favipiravir Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Favipiravir Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Favipiravir Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Favipiravir Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Favipiravir Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Favipiravir Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Favipiravir Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Favipiravir Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Favipiravir Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Favipiravir Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Favipiravir Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Favipiravir Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Favipiravir Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Favipiravir Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ChemRar Group
  2. 8.1.1 ChemRar Group Company Information
  3. 8.1.2 ChemRar Group Business Overview
  4. 8.1.3 ChemRar Group Favipiravir Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ChemRar Group Favipiravir Product Portfolio
  6. 8.1.5 ChemRar Group Recent Developments
  7. 8.2 Cipla
  8. 8.2.1 Cipla Company Information
  9. 8.2.2 Cipla Business Overview
  10. 8.2.3 Cipla Favipiravir Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Favipiravir Product Portfolio
  12. 8.2.5 Cipla Recent Developments
  13. 8.3 Dr. Reddy
  14. 8.3.1 Dr. Reddy Company Information
  15. 8.3.2 Dr. Reddy Business Overview
  16. 8.3.3 Dr. Reddy Favipiravir Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Reddy Favipiravir Product Portfolio
  18. 8.3.5 Dr. Reddy Recent Developments
  19. 8.4 Fujifilm
  20. 8.4.1 Fujifilm Company Information
  21. 8.4.2 Fujifilm Business Overview
  22. 8.4.3 Fujifilm Favipiravir Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fujifilm Favipiravir Product Portfolio
  24. 8.4.5 Fujifilm Recent Developments
  25. 8.5 Glenmark
  26. 8.5.1 Glenmark Company Information
  27. 8.5.2 Glenmark Business Overview
  28. 8.5.3 Glenmark Favipiravir Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Favipiravir Product Portfolio
  30. 8.5.5 Glenmark Recent Developments
  31. 8.6 Lupin
  32. 8.6.1 Lupin Company Information
  33. 8.6.2 Lupin Business Overview
  34. 8.6.3 Lupin Favipiravir Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Favipiravir Product Portfolio
  36. 8.6.5 Lupin Recent Developments
  37. 8.7 R-Pharma
  38. 8.7.1 R-Pharma Company Information
  39. 8.7.2 R-Pharma Business Overview
  40. 8.7.3 R-Pharma Favipiravir Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 R-Pharma Favipiravir Product Portfolio
  42. 8.7.5 R-Pharma Recent Developments
  43. 8.8 Sun Pharma
  44. 8.8.1 Sun Pharma Company Information
  45. 8.8.2 Sun Pharma Business Overview
  46. 8.8.3 Sun Pharma Favipiravir Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharma Favipiravir Product Portfolio
  48. 8.8.5 Sun Pharma Recent Developments
  49. 8.9 Hisun Pharm
  50. 8.9.1 Hisun Pharm Company Information
  51. 8.9.2 Hisun Pharm Business Overview
  52. 8.9.3 Hisun Pharm Favipiravir Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hisun Pharm Favipiravir Product Portfolio
  54. 8.9.5 Hisun Pharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Favipiravir Value Chain Analysis
  2. 9.1.1 Favipiravir Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Favipiravir Sales Mode & Process
  6. 9.2 Favipiravir Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Favipiravir Distributors
  9. 9.2.3 Favipiravir Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst